Joachim Eeckhout, Author at Labiotech.eu - Page 11 of 16

About

Founder & Managing Director at Labiotech.eu. While I was studying biotechnology in Paris, I got frustrated by the lack of digital media available for the industry and decided to fix it! I launched Labiotech.eu in 2014 and grew it to the largest community for biotech professionals in Europe! Other than biotech news, I’m also a heavy reader of Sci-Fi and Fantasy.

Articles by Joachim Eeckhout

clinCapture

News and Trends 8 Jun 2015

An Easy Solution to Lower the Time and Costs of Clinical Trials

With the technology advances we have seen in the last 10 years, it’s hard to believe that, only 50% of clinical trials are using Electronic Data Capture (EDC), whilst the other 50% are still being run on paper and in Excel spreadsheets. Why is this adoption rate so low? The answer lies in the cost and […]

June 8, 2015 - 3 minutesmins - By Joachim Eeckhout

piooneer

News and Trends 4 Jun 2015

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Last week, Biotech Entrepreneurs gathered in Berlin for the Charité Entrepreneurship Summit 2015. As a spectator, I’ll bring you the most important lessons to take on board from successful entrepreneurs. The First speaker was James Sabry, Senior VP at Genentech, which I already interviewed on the strategy of Genentech/Roche. The Californian entrepreneur, who founded the NASDAQ-listed company Cytokinetics before joining Genentech, gave […]

June 4, 2015 - 4 minutesmins - By Joachim Eeckhout

avantium

News and Trends 3 Jun 2015

Avantium’s bioplastic, latest Green Hope for the Agribusiness?

After many awards and famous collaborations, the Dutch biotech company Avantium signed a deal with Tereos for the production of its 100% biobased plastic. The Bioplastic provider is moving forward to disrupt an established market! Initially created as a spin off of Shell, Avantium is a 15 years old Dutch company specialized in the area of advanced […]

June 3, 2015 - 2 minutesmins - By Joachim Eeckhout

active biotech1

News and Trends 2 Jun 2015

After Failing Phase III, Active Biotech is back to square one

Unfortunately, the Biotech world is not only composed of success stories. Active Biotech, a Swedish company focused on developing treatments for neurodegenerative diseases and cancer. The company, engaged with Ipsen, discontinued a Phase III study and is currently discovering the consequences of this failure the hard way. Active Biotech’s business model, like many small red biotechs, is based on partnering with […]

June 2, 2015 - 2 minutesmins - By Joachim Eeckhout

Hyglos

News and Trends 29 May 2015

Hyglos has a Solution Against Resistant Hospital Germs

Germany-based Hyglos and scientists from the universities of Tübingen, Münster and Munich join forces to develop a phage-based active substance against the dreaded hospital pathogen Staphylococcus aureus. Their secret lies in a highly effective protein from bacteria-specific viruses, the so-called bacteriophages, capable of rapidly killing the bacteria, which frequently occur in the nose. Due to the specific action of this […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

Cellectis

News and Trends 29 May 2015

Pfizer to Control Cellectis in a €1.5 Billion Deal?

Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers. According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

ADVERTISEMENT

Poxel japan

News and Trends 29 May 2015

Poxel is Looking towards Japan’s Lucrative Diabetes Market

Poxel, the French company that made a €27M IPO last February, announced the successful conclusion of a phase 1 clinical trial in Japanese subjects with Imeglimin, its lead drug candidate. Imeglimin has already completed phase 2 clinical trials in type 2 diabetes patients in the US and EU and is ready for Phase III. This […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

deinove photo

News and Trends 28 May 2015

Deinove Reaches Critical Milestones and Gets Recognition in the US

May 2015 is a great month for Deinove! The French company focused on Deinococci bacteria for green chemistry. Deinove reached critical milestone achievements in its industrial collaboration with Avril and their scientists gained major recognition in the US. Deinove is definitely on the front of the stage! A few days ago, Emmanuel Petiot, CEO of Deinove, declared that “All Deinove teams are […]

May 28, 2015 - 2 minutesmins - By Joachim Eeckhout

berlin biotech

News and Trends 27 May 2015

Berlin’s biotech ecosystem, a fast-growing European hotspot

The Bionnale 2015, a major networking event for biotech in Berlin, is taking place today. Talks about Berlin’s cluster gave me a good insight on what’s happening here. Don’t expect Berlin to be a groundbreaking place like Boston or San Diego. The German capital has more conventional assets, but they’re definitely building a solid ecosystem. With more […]

May 27, 2015 - 3 minutesmins - By Joachim Eeckhout

invectys

News and Trends 25 May 2015

Invectys focuses on Telomers to develop a Universal Cancer Vaccine

French startup Invectys believes to have found the solution to cancer: one vaccine to cure them all! By targeting telomerase, this new immunotherapy could theoretically fight 95 % of all human cancers. When a cell divides, a small piece of DNA, called telomere, is lost at both ends of each chromosome. Telomerase adds these pieces of DNA again at the end of […]

May 25, 2015 - 3 minutesmins - By Joachim Eeckhout

Genzyme

News and Trends 22 May 2015

Genzyme joins the never-ending list of Ablynx’ partners

Genzyme is joining Ablynx’ partner list, which already includes AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Sanofi subsidiary now wants to try out the Nanobody technology of Ablynx against a target at the origin of multiple sclerosis. Genzyme wants to investigate nanobodies against a target that specifically aligns with Genzyme’s early-stage multiple […]

May 22, 2015 - 2 minutesmins - By Joachim Eeckhout

biosyntia andreas

News and Trends 20 May 2015

Danish Startup Biosyntia grabs €1.7M to Inject Synthetic Biology into Vitamin Production

Biosyntia is a Danish start-up company in the synthetic biology field. The company aims at replacing chemical-based vitamin production by sustainable and fermentation-based processes. Yesterday, during our Denmark Biotech Tour, we met Andreas Laustsen, one of Biosyntia‘ founders who told us that the company has just raised €1,7M from Novo Seeds. The startup was founded in 2012 by […]

May 20, 2015 - 2 minutesmins - By Joachim Eeckhout

ADVERTISEMENT